Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

SURG-05. EXPERIENCE PROFILING OF FLUORESCENCE-GUIDED SURGERY FOR GLIOMAS

View through CrossRef
Abstract Numerous studies reported a usefulness of 5-ALA fluorescence-guided surgery (FGS) in high grade gliomas. However, fluorescence pattern and intensity is variable among gliomas. In this study, we report our extensive experiences of FGS in various gliomas focusing on epidemiological data of fluorescence pattern. A total of 827 histologically proven glioma patients out of 900 brain tumor patients who had undergone FGS using 5-ALA during the period of 8.5 years between July 2010 and January 2019 were analyzed. Indication for FGS in glioma surgery harbored any evidence of possible high-grade foci at presumed gliomas in preoperative magnetic resonance images (MRI). Among the 827 gliomas, the number of cases corresponding to 2016 World Health Organization (WHO) grade IV, III, II, and I are 528 (58.7%), 193 (21.4%), 87 (9.7%) and 19 (2.1%), respectively. In terms of fluorescence rate, grade IV gliomas showed positive fluorescence in 95.4% of cases including strong intensity in 85.6%. Grade III gliomas showed fluorescence in about half of cases (55.0%), while 45.0% of cases did not show any fluorescence. Anaplastic oligodendroglioma had more positive rate (63.9%) than anaplastic astrocytoma (46.2%). Both grade II and I gliomas still showed positive fluorescence in about one-fourths of cases (24.1% and 26.3%, respectively). Among them ependymoma and pilocytic astrocytoma were fluorescence-prone tumors. This epidemiological data of 5-ALA fluorescence in various grades of gliomas provides fundamental reference to clinical application of FGS using 5-ALA in glioma surgery.
Title: SURG-05. EXPERIENCE PROFILING OF FLUORESCENCE-GUIDED SURGERY FOR GLIOMAS
Description:
Abstract Numerous studies reported a usefulness of 5-ALA fluorescence-guided surgery (FGS) in high grade gliomas.
However, fluorescence pattern and intensity is variable among gliomas.
In this study, we report our extensive experiences of FGS in various gliomas focusing on epidemiological data of fluorescence pattern.
A total of 827 histologically proven glioma patients out of 900 brain tumor patients who had undergone FGS using 5-ALA during the period of 8.
5 years between July 2010 and January 2019 were analyzed.
Indication for FGS in glioma surgery harbored any evidence of possible high-grade foci at presumed gliomas in preoperative magnetic resonance images (MRI).
Among the 827 gliomas, the number of cases corresponding to 2016 World Health Organization (WHO) grade IV, III, II, and I are 528 (58.
7%), 193 (21.
4%), 87 (9.
7%) and 19 (2.
1%), respectively.
In terms of fluorescence rate, grade IV gliomas showed positive fluorescence in 95.
4% of cases including strong intensity in 85.
6%.
Grade III gliomas showed fluorescence in about half of cases (55.
0%), while 45.
0% of cases did not show any fluorescence.
Anaplastic oligodendroglioma had more positive rate (63.
9%) than anaplastic astrocytoma (46.
2%).
Both grade II and I gliomas still showed positive fluorescence in about one-fourths of cases (24.
1% and 26.
3%, respectively).
Among them ependymoma and pilocytic astrocytoma were fluorescence-prone tumors.
This epidemiological data of 5-ALA fluorescence in various grades of gliomas provides fundamental reference to clinical application of FGS using 5-ALA in glioma surgery.

Related Results

Abstract 4113: A multimodal (PET/NIRF) smart probe for selectively identifying, grading, and visualizing astrocytic gliomas
Abstract 4113: A multimodal (PET/NIRF) smart probe for selectively identifying, grading, and visualizing astrocytic gliomas
Abstract Astrocytic gliomas are the most common glioma subtype and constitute the majority of all primary brain tumor types. The malignancy of an astrocytic glioma i...
Molecular classification of adult gliomas: recent advances and future perspectives
Molecular classification of adult gliomas: recent advances and future perspectives
Purpose of review This review summarizes recent advances in the molecular classification of adult gliomas. Recent findings ...
Abstract 1345: Mutant IDH1 and tissue factor in gliomas
Abstract 1345: Mutant IDH1 and tissue factor in gliomas
Abstract Background: IDH1 mutations (IDH1mut) occur in 20-30% of gliomas, induce DNA hypermethylation, and are associated with a better prognosis than IDH1 wild-type...
BIOM-17. DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
BIOM-17. DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
Abstract INTRODUCTION IDH mutations are a defining feature of lower-grade glioma and secondary glioblastoma. Approximately 95% o...
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
Background Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%–75%. The primary and secondary brain malign...
Optimising primary molecular profiling in NSCLC
Optimising primary molecular profiling in NSCLC
AbstractIntroductionMolecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular profiling...
CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis
CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis
Background and ObjectivePossible treatment strategies for recurrent malignant gliomas include surgery, chemotherapy, radiotherapy, and combined treatments. Among different reirradi...
MicroRNAs in high-grade gliomas: What is their role?
MicroRNAs in high-grade gliomas: What is their role?
High-grade gliomas are malignant tumours of the central nervous system with poor overall survival. Equivalently, glioblastoma is one of the most devastating brain tumours. Treatmen...

Back to Top